An observational study in Prostate Cancer, sponsored by Ferring Pharmaceuticals. Completed at 47 sites in Netherlands. Open to male participants. Per ClinicalTrials.gov, last updated 2015-08-19.
Sponsored by Ferring Pharmaceuticals · Observational
Patients eligible for hormone ablation therapy who are prescribed Firmagon will be followed for a maximum of 3 years to estimate the progression free survival. Data on testosteron levels, QoL and LUTS will be collected if this information is available. Safety information (adverse events) will be collected.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's enrollment of 274 is above the median of 200 across 1,181 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with advanced prostate cancer
Exclusion Criteria:
To estimate the progression-free survival (PFS) failure rate
Time frame: Maximum 3 years
To enhance the knowledge on known undesirable effects under routine conditions and to obtain further knowledge about so far unknown and rare undesired effects
Time frame: Every 3 months (during 3 years)
To prescribe the change in patient's quality of life (QoL) during therapy.
Time frame: From study start and after 6 months
To assess the improvement of IPSS from baseline after 3 months of Firmagon therapy and at end-of-therapy
Time frame: From study start, after 3 months and at end of treatment
To assess the reduction of prostate volume (neoadjuvant therapy)
Time frame: Fom baseline after 3 months
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ferring Pharmaceuticals